{
  "doc_id": "Relatório de avaliação de financiamento público  de Lumykras (sotorasib)",
  "created_date": "2015",
  "country": "PT",
  "source_type": "hta_submission",
  "chunks": [
    {
      "heading": "",
      "text": "RE LUM Treatment advances therapeutic evaluation INFAR MYKRAS EVALUATION ELATORY PUBLIC (SOTORASIB) treatment of adult patients with non-small cell lung cancer (NSCLC) with a mutated KRAS G12C and who have progressed after at least one systemic line of sight prior to funding under Decree-Law No 97/2015, of 1 June, in its current wording.",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "If you have any further questions on the use of this product, please contact your doctor or pharmacist for further information. • Do not inject any other medicines.",
      "text": "What Sotorasib looks like and contents of the pack 240 film-coated tablets, 120 mg, registration number 5832027 MAH: Amgen Europe, B.V.",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "The assessment report shall be submitted to the competent authority of the Member State in which the applicant has its registered office or place of business and shall include the following information:",
      "text": "This conclusion was based on the following facts: - Sotorasib data from the interim analysis of the Phase III CodeBreaK 200 clinical trial showed no difference in overall survival between treatment groups, with a difference in progression-free survival of 1.1 month compared to the comparator alternative (KRAS G12C mutated) and having progressed after at least one prior systemic line of therapy.",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "1.Epidemiology and characterization of the disease 1.Epizootic diseases and their causes 2.Epidemics of disease",
      "text": "Lung cancer is the most commonly diagnosed oncological disease worldwide (excluding non-melanocytic skin neoplasms) and the leading cause of death from cancer worldwide. Globally, only 18% of patients are estimated to be alive 5 years or more after diagnosis of the disease. Most patients are diagnosed at an advanced stage (not curable), so os incidence and mortality numbers are very similar.",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "2.Description of the technology and therapeutic alternatives. 2.Details of the clinical trials carried out by the laboratory.",
      "text": "LUMYCRAS (sotorasib) is an antiretroviral agent with a covalent and irreversible inhibitor of the KRAS G12C/MEDM012 alpha-beta-glucanase (β-glycanase) in the MEDM014 cells with an estimated plasma toxicity of up to 75 mg/day. This is an anticonvulsant drug with an anti-inflammatory effect on the MedM010-G12C cells. In MEDM114 cells, inactivation of MedM112 by MEDM12 prevents signaling, inhibits growth and promotes selective apoptosis in tumors carrying MedM12M12G, with minimal detectable activity outside of this target. MEDMED12M is currently being treated with the only MedMED011G12M inhibitor approved by the European Medicines Agency, at a dosage of 960 mg/ day POF, until cell disease progression or unacceptable toxicity has been measured. However, only recently, it has been possible to robustly assess the prevalence of the p.G12C mutation in patients with NSCLC. To do this, it is necessary to use data from the AACR GENIE registry, an international registry with information from 19 of the main cancer treatment centers in the world. In this Lumykras (MEDTERM00) registry there were a total of 13,243 patients with CPNPC, of which 29,0% (n=3838) had a MEDTERN011 mutation and 12,1% (n = 1604) had specifically the MEDTERP011 p. G12C. Applying this value to the Portuguese one, it can be concluded that, of the 4,603 cases of CPNPN diagnosed annually, about 55 (12,1%) will be MEDTERB011 positive.",
      "start_page": 4,
      "end_page": 6
    },
    {
      "heading": "3. Indicações e comparadores selecionados para a avaliação",
      "text": "Table 1 shows the population, intervention and comparators selected for evaluation of Sotorasib. Table 1: Population, Intervention and Comparators Selected Adults with cancer of the Medterm006 docetaxel, Used routinely in the lung of non-small cell clinical practice; Median duration of medication: 200 mg or less than 200 mg daily or 200 mg twice daily; Medication: 250 mg or 500 mg once daily or twice daily from the Median Duration of treatment: 300 mg or twice a day; Medications: 200mg or 200mg twice daily or once a week; Medicines: 500 mg or once daily from Medium duration to Medium Duration; Medicinal products: 500mg or once per day from Median to Median. Table 3: Outcome measures and ranking of importance Evaluation measures Score* Rating of importance of measures* Measures of effectiveness Overall survival 9 Critical Progression-free survival 6 Important Response rate 5 Important Quality of life 9 Critique Safety measures Adverse event rate Important 6 Rate of adverse events G3-4 7 Critical Dropout rate by 8 Critical toxicity Mortality related to the 9 Critically important medicinal product",
      "start_page": 6,
      "end_page": 9
    },
    {
      "heading": "5.Description of the studies evaluated; and/or a summary of the results of the evaluation; and /or a description of the study.",
      "text": "All os studies were considered relevant for the present evaluation, namely the CodeBreaK 100 and 200 studies given their prior response or baseline response to the MEDTC019 study (MEDC0100) or the CodeM0100 study (CodeM0200), which were evaluated by the MEDC019 Committee on the basis of a combination of placebo, placebo, or placebo-controlled treatment. (TERM) All patients were assessed at the end of the study as having either a positive or negative response to treatment. The response was elaborated in frequency and percentages, os confidence intervals were 95% calculated by the Clopper-Pearson method.   16 studies were carried out on the basis of the original MEDM19M methodology, namely a combination of the MEDM17M and MEDM14M studies carried out without prior publication by the MEDC19M Research Centre (MEDC16M)  Requirements were summarised using the Kaplan-Meier and 95% confidence interval estimates of the captive and non-captive MEDMED19M studies were not included in the original C19M study (Coordinator: MEDM18M) in the UK (Medic19M Reviewer: MEDC20M) (MediClinical Review Systematic Review of Literature and Indirect Comparison Study Declarations, 2003);  A comparison of the eight studies were included with the MACT_MEDM Reviews in the United Kingdom (Publication Number: 2011); ‡  a comparison between the METMED_M11M studies performed in the OCT1 and MEDC17M Reflectation Centre (REF_M) and the RS19M16M studies conducted without previously carried out by the C17M10M study. os main reasons identified were absence of additional comparators of interest (76.5%, n=13); lack of crucial information for achieving the MAIC in the population of interest (MEDTERM 012 G12C), or in the extended population of mutated MEDDERM012 (23.5%, n = 4) so that the only feasible indirect comparison in patients with previously treated advanced CPNPC was the efficacy of MEDM013 versus MEDTERm 012 or mutated CPNCC, based on the results of the CodeB 100 study (sensitivity) and SELECT-1 (age-determining) STERM 100 (responsibility) study. With regard to the comparative safety analysis, in the CodeBreaK 100 study, 57 (45.3%) patients had adverse drug reactions of grade three (42.1%) or four (3.2%) that occurred at the end of each treatment period (1 month to 6 months) from the previous MEDClinic study to the end-of-medication study involving the MEDMED1900 study, 32 percent of patients treated with MEDMERM6 were assessed by the MED1900 trial's central linear control regimen (MEDM1900), 32 percent were considered to have experienced adverse medication reactions until 6 months after initiation of treatment. [007MM] had occurred in [006MM], [130MM]. [114MM.] [250MM.], [115M.] [004M.] had been administered by the MEDMED group [0015M]. [0016M] [0014M.]. [150M.M.] [1157M.] [1050M.] [1500M.] at the last trial date. [0024M.] [615M] at the end of the trial period. [1200M.] [750M] At the time of completion of the first trial, [002M.] the MEDTERM group (MEDTERM) was the last group to receive the MEDTERM experimental data. [100M] % of participants were 18 years of age and had locally advanced and irreversible or metastatic CPNPC mutation with histologically documented MEDTTERM012 p.G12C mutation and no other known oncogenic mutation for which an approved targeted therapy exists. At the data cut-off date for this report, 25 crossover patients (54.3%) remained in the study, and 21 crossovers patients (45.7%) discontinued the study for the following reasons: total death (17 patients) [37.0%) and withdrawal of patient consent (48.0%) from the MEDICM group (MEDICM Group), Atherosclerosis, OTERTERM, ATERM (TERM), ATERTERS, AETERM, MEDTERM) and ATERS (TERMS) groups. A median median survival of os was 10.6 months (IC 95%: 8.9; 14.0); a median response time of 46.0 months (TERM) was calculated for all participants in the MEDICOM (MEDICOM) treatment group with MEDICORM at 16.03 months, MEDICM at 13.12 months and MEDICMO at 16.12 months, with MEDCOM at 13.03 months and with MEDMICOM at 12.12 months.",
      "start_page": 9,
      "end_page": 22
    },
    {
      "heading": "♪ I'm the one who's got it all ♪ ♪ I don't know what to do with it, but I can't help it ♪",
      "text": "In terms of change from the start of the study to week 12 (MMRM analysis), the median change of the minimum squares (LS) was 6.93 (IC 95%: 3.66; 10.19) for overall health status, 8.78 (CI 95%: 5.39; 12.17) for physical function, the mean change (EP) of the LS within the group was 0.03 (1.45) for global health status/QV, 0.10 (1.48) for physical functionality, and -0.57 (1.41) for positive dyspnoea (compounding) in the MEDICM QLQ-C30 and -1.59 (16.008) for total health status). Adverse event rate G3-4 Grade ≥ 3 adverse events were reported in 121 patients (71.6%) in the sotorasib group and 91 patients (60.3%) in docetaxel, and the exposure-adjusted event rates were 177.4 and 271.2, respectively.Treatment-related adverse event rates of Grade 3 were reported for 56 patients (33.1%) in MEDterm000 and 61 patients (40.00%) in docetaxel group, and the treatment- adjusted events rates were 15.3 and 34.4%, respectively; Grade 1 adverse effects reported for 131 patients (98.0%) and 119 patients (70.6%) and 167.0%) were reported as adverse drug-related events in the MediTERM001 group.",
      "start_page": 22,
      "end_page": 25
    },
    {
      "heading": "Evaluation of the evidence by outcomes (e.g. in the case of a clinical trial) and the outcome of the trial.",
      "text": "The additional benefit of Sotorasib was analysed against the available comparator alternatives, for each outcome measure [90,090 to 95], [90,980 to 95] This initial evaluation matrix consisted of 95 patients [91,984 to 955] with a median survival rate of 9.05% in the 3-month MEDICM III trial with 19.045 patients (for adenocarcinomas), 7.003 patients in the extended-lifetime MEDCICM (for non-predominantly squamous histology), 10.004 participants in the exploratory MEDMICM trial (for tumors expressing MEDCIM7 with a TPS >=1%), MEDTERM1 patients with 0.006 patients in an ICM3M (medicamentally untreated patients) and 10.005 patients in a MEDCIIM (median survivors) group (for clinically unacceptable events) with an average survival time of 0.002 months compared to the median 0.0055%).",
      "start_page": 25,
      "end_page": 27
    },
    {
      "heading": "7. Quality of the evidence submitted to the Court of First Instance and of the case-law of the European Court of Auditors; and",
      "text": "Methodological issues that could reduce confidence in effect estimates were considered. TAIM submitted a phase 1-2 clinical trial, an indirect comparison analysis by MAIC, and interim data from a phase 3 controlled clinical study. Overall quality of evidence was classified as moderate, as a consequence of the immaturity of the overall survival results. Moderate quality means moderate certainty of results (meaning: we are moderately confident in the effect estimate. The true effect is likely to be close to the estimated effect, but there is a possibility that it may be substantially different).",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "8. Evaluation and comments on the evidence submitted by the parties to the proceeding (Article 8 (1) (b) of the Rules of Procedure)",
      "text": "The additional benefit of MEDTERM (Lumykras) was assessed in the indication of treatment of adult patients with advanced non-small cell lung cancer (NSCLC) [950-955] [980-950] [950-800] [1050-900] [9100-9500] [10100-9005] [9100-8005] [10100-1000] [10000-9006] [10100] [1200-200] [10200] [1001001] [101001] [12002] [102001] [102002] [12003] [102004] [102005] [12005] [102006] [102007] [12007] [102008] [12008] [102009] [12009] [2008] [2009]] [2002] [2004] [2005] [2006] [2007] [72008] This assessment was carried out by the MEDC] MEDC[2008] and MEDMEDC[1001] [1002] [1003] [1004] [1005] [1006] [1007] [1008] [1009] [10010] [10011] [1001] ] [10014] [10016] [10017] [10018] [10019] [10020] [10012] [10013] [1001 ] [2001] This assessment has been performed by the following: • Os data from the interim analysis of the Phase III CodeBreaK 200 clinical trial showed no difference in overall survival between treatment groups, with a difference in progression-free survival of 1.1 months compared to the comparator alternative docetaxel (HR 0.66 [95%CI: 0.51, 0.86], p-value = 0.002), with improvement in the 12-month progression assessment (24.8% vs 10.1%) and objective response rate (28.1% [95% CI: 21.5, 35.4] vs 13.2% [95% IC: 8.6], • sotorasib showed a similar safety profile to MEDTER M005. • No data are available to compare MEDTER m002 and any of the remaining comparator alternatives indicated in the evaluation matrix.",
      "start_page": 27,
      "end_page": 29
    },
    {
      "heading": "10 - Economic evaluation of the measures to be taken by the Member States in the framework of the common foreign and security policy (CFSP)",
      "text": "Not applicable to the case of a newly registered company. . . . , . . .. . . ... . . ! . . ? . .",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "11. Conclusions of the Court of Auditors' Opinions . . .. . . , . . .. . . ! .",
      "text": "This conclusion was based on the following facts: - Lumykras (Sotorasib) was pre-evaluated for public funding for the treatment of patients with advanced non-small cell lung cancer (ASCLC) who had progressed after at least one prior systemic line of therapy with mutated KRAS G12C. Compared to the comparator docetaxel, the medicine did not demonstrate added therapeutic value, so it was not funded for this indication. This was based upon the following: - Os data from the interim analysis of the phase III clinical trial Krea 200 showed no difference in overall survival between treatment groups, with a difference in progression-free survival of 1.1 months compared to the alternative comparator Medter MHRM2 (9.66%: 0.001, 0.002, 0.005, 0.006, 0.008%) and an improvement in the safety profile of Medter-M2 compared to any of the remaining medicinal products (98.5% vs. 12.5%).",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "12 - References in the literature and other publications of the European Communities (OJ C 180, 1.7.1993). . . .",
      "text": "Amgen Inc., A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 540 Combination Therapy inSubjects with Advanced NSCLC With MEDterm004 P.G.12C mutation (CodeBreak 100) (data on file 2020.) Amgen, A systematic literature review (S) of randomized controlled trials (RCTs) to evaluate the comparative safety and effectiveness of second-line systemic therapy for metastatic cancer in adults with advanced solid tumors with active or non-small cell lung cancer (docetaxel4) AMG, Inc. is a clinical trial that has been conducted in the United States and Canada.",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "Table 1 on page 9 is replaced by the following: 'Table 2 on page 10' . 'Tables 2 and 3 ' . '",
      "text": "Table contains the following columns: Measures of assessment, Column_2, Score*, column_4, Classification of,Column_6 Row 1: Measure of: importance of Row 2: Measure of: measures* Row 3: Column__2: Measurement of efficacy Row 4: Measuring of: overall survival, Score*: 9, and Column___4: Criticism Row 5: Measurer of: progression-free survival Score: 6, and column__4: Important 6: Measurers of: response rate, Scores*: 5, andcolumn_4: Important Row 7: Measurs of: quality of life, scores*:9 and Columna_4: Critical: Row 8: Safety measures: Row 9: Measured on: adverse event rate, Secondary score* Score:* Column and_6: Important: measures of: effectiveness Row 4: Evaluation of: survival rate, G-related events Score of: 11: 3-4, and Colonne_4: Adverse event-related mortality and morbidity Score, Row 7: Mortality and toxicity score*",
      "start_page": 9,
      "end_page": 9,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 13,
        "extraction_method": "pass_1_standard",
        "has_title": false,
        "page": 9,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": false,
        "table_title": null,
        "narrative_length": 1050
      }
    }
  ],
  "_table_detection_summary": {
    "total_tables_found": 1,
    "tables_by_page": {
      "9": [
        {
          "heading": "Table 1 on page 9",
          "narrative_length": 1050,
          "extraction_method": "pass_1_standard",
          "original_rows": 13,
          "primary_content_type": "general",
          "contains_medical_data": false
        }
      ]
    },
    "table_storage_info": "Tables stored as individual chunks with hybrid metadata (narrative + structured)",
    "medical_table_insights": {
      "pricing_tables": 0,
      "dosage_tables": 0,
      "medication_tables": 0,
      "multi_pass_detection_summary": {
        "pass_1_standard": 1,
        "pass_2_relaxed": 0,
        "pass_3_medical": 0
      }
    }
  },
  "_translation_metadata": {
    "processing_timestamp": "2025-08-11T09:36:58.172411",
    "source_file": "Relatório de avaliação de financiamento público  de Lumykras (sotorasib)_cleaned.json",
    "detected_language": "pt",
    "was_translation_needed": true,
    "model_attempts": [
      {
        "model_loaded": true,
        "model_name": "facebook/nllb-200-3.3B",
        "processing_time_seconds": 476.492583,
        "chunks_found": true,
        "total_chunks": 15,
        "chunks_translated": 28,
        "chunks_english": 1,
        "table_chunks_processed": 2,
        "quality_scores": {
          "overall": 0.845156695156695,
          "english_quality": 1.0,
          "medical_preservation": 0.6606267806267806,
          "has_placeholders": 0.13333333333333333,
          "length_score": 0.7,
          "chunk_count": 15
        }
      }
    ],
    "final_model_used": "facebook/nllb-200-3.3B",
    "retranslation_occurred": false,
    "quality_comparison": {},
    "final_quality_scores": {
      "overall": 0.845156695156695,
      "english_quality": 1.0,
      "medical_preservation": 0.6606267806267806,
      "has_placeholders": 0.13333333333333333,
      "length_score": 0.7,
      "chunk_count": 15
    },
    "chunks_translated": 10,
    "chunks_preserved_english": 19,
    "table_chunks_processed": 2,
    "total_processing_time_seconds": 491.399186,
    "translation_strategy": "enforced_language_codes",
    "medical_preservation_used": "whitelist_approach",
    "table_content_detected": 2,
    "models_available": true,
    "available_models": [
      "facebook/nllb-200-3.3B",
      "facebook/nllb-200-1.3B",
      "facebook/nllb-200-distilled-1.3B",
      "facebook/nllb-200-distilled-600M"
    ],
    "translation_decision": "translation_completed",
    "processing_completed_timestamp": "2025-08-11T09:45:09.571605"
  }
}